Related Experiment Videos
Depression in the medically ill: management considerations
1Department of Psychiatry, University of Florida College of Medicine, Gainesville 32610, USA.
Insights
Managing depression in patients with coronary artery disease (CAD), cancer, or HIV is crucial. Antidepressant therapy, particularly SSRIs, can improve outcomes and quality of life while minimizing risks associated with older antidepressants.
Area of Science:
- Medical management
- Psychiatry
- Cardiology
- Oncology
- Infectious Diseases
Background:
- Depression frequently co-occurs with serious medical conditions like coronary artery disease (CAD), cancer, and HIV.
- Major depression is linked to increased mortality in CAD patients, potentially via reduced heart rate variability.
- Certain antidepressants carry risks; tricyclic antidepressants (TCAs) may increase sudden death risk and decrease heart rate variability.
Purpose of the Study:
- To review the management of depression in patients with CAD, cancer, and HIV.
- To discuss the efficacy and safety of different antidepressant classes in these patient populations.
- To highlight the role of psychosocial interventions in managing depression in these conditions.
Main Methods:
- Literature review of studies on depression management in CAD, cancer, and HIV.
- Analysis of the impact of depression on mortality and quality of life.
- Evaluation of antidepressant therapies, including TCAs, SSRIs, and newer agents.
- Consideration of non-pharmacological interventions like social support and coping skills.
Main Results:
- Antidepressant therapy is effective for improving quality of life in cancer and HIV patients.
- SSRIs and newer antidepressants are preferred due to fewer adverse anticholinergic and cardiovascular effects compared to TCAs.
- Psychosocial interventions can positively influence outcomes in cancer and HIV patients.
- Depression management in CAD requires careful consideration of cardiac risks associated with certain antidepressants.
Conclusions:
- Effective management of depression in patients with CAD, cancer, and HIV is essential for improving outcomes.
- SSRIs and newer agents offer a safer alternative to TCAs for depressed patients with medical comorbidities.
- Integrating psychosocial support alongside pharmacotherapy can enhance patient well-being and coping mechanisms.
Abstract:
This article reviews the management of depression in three medical conditions associated with a high frequency of depression: coronary artery disease (CAD), cancer, and human immunodeficiency virus (HIV) infection. Major depression significantly increases mortality in patients with CAD. This effect of depression may be mediated by a decrease in heart rate variability. Tricyclic antidepressants (TCAs) possess Type 1A antiarrhythmic activity, which may increase the risk of sudden death. Initial data suggest that tricyclic antidepressants also may decrease heart rate variability. Antidepressant therapy is effective and can improve quality of life for patients with cancer or HIV infection. Strong social support or psychosocial interventions that improve coping skills may positively affect outcome in HIV infection and cancer. Selective serotonin reuptake inhibitors (SSRIs) and new agents may be well suited for use in depressed patients with medical illnesses because they lack the significant adverse anticholinergic and cardiovascular effects of TCAs and other classes of antidepressants.